Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Sei Investments Co.

Sei Investments Co. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 624,800 shares of the medical research company’s stock after buying an additional 49,451 shares during the quarter. Sei Investments Co. owned approximately 1.21% of Charles River Laboratories International worth $129,072,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International in the first quarter valued at approximately $41,000. Brown Brothers Harriman & Co. raised its stake in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after buying an additional 193 shares in the last quarter. Finally, Concord Wealth Partners grew its stake in Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 203 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $205.79 on Friday. The stock has a market cap of $10.60 billion, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 3.89 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The firm has a 50 day simple moving average of $209.34 and a 200-day simple moving average of $224.06. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.03 billion. On average, analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its board has approved a share buyback plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have issued reports on CRL. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a report on Monday, August 12th. Mizuho began coverage on Charles River Laboratories International in a report on Friday, June 7th. They issued a “neutral” rating and a $235.00 price objective on the stock. Robert W. Baird reduced their target price on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday. The Goldman Sachs Group lowered their price target on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $230.93.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).